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PURPOSE. Trachoma remains a leading cause of blindness. De-
termining the most effective antibiotic treatment strategy is
essential for the success of country-based trachoma control
programs.
METHODS. Baseline and 2-month follow-up examinations were
performed in a trachoma-hyperendemic village. All residents
were offered azithromycin for trachoma after baseline was
determined. Infection with Chlamydia trachomatis and chla-
mydial load were determined by PCR. Clinical trachoma status
was evaluated. A high chlamydial load was defined as a higher
than median chlamydial load among those with infection. Risk
factors were examined in multiple logistic regression models.
Associations are presented as odds ratios and 95% confidence
intervals.
RESULTS. At baseline, 57% of participants were infected with
C. trachomatis. Although clinical trachoma correlated with
infection, 23% of participants with high chlamydial loads
showed no clinical signs. Adults represented only 10% of the
population with high loads. Treatment significantly de-
creased the proportion positive in the community and the
load in the community. However, 27% of individuals with
high loads at baseline who received treatment also were
infected at 2 months. Of those, 93% with high loads at 2
months were aged 10 years.
CONCLUSIONS. Although most of the chlamydial load in this
community resided in children, 10% of the high load resided in
adults, most of whom did not have follicular trachoma and in
whom the infection would be missed under treatment strate-
gies that focus on clinical disease or children. These data
support a mass treatment strategy for hyperendemic commu-
nities, at least as a first approach. In addition, treatment of
children age 2 years should be reexamined, as 30% with
high loads at baseline remained infected at 2 months, despite
monitored treatment according to weight. (Invest Ophthalmol
Vis Sci. 2005;46:83–87) DOI:10.1167/iovs.04-0327
Trachoma continues to be the leading infectious cause ofblindness worldwide, and the target of a World Health
Organization (WHO) initiative for the Global Elimination of
Blinding Trachoma by 2020 (GET 2020).1 Several countries in
which trachoma is endemic have started national trachoma-
control programs, by using a multifaceted strategy known as
SAFE2: surgery, antibiotics, face washing, and environmental
improvement. The antibiotic, face washing, and environmental
improvement components of SAFE are targeted toward reduc-
tion of active trachoma within communities.
Where active trachoma is hyperendemic, the prevalence in
preschool children may be 70% or higher,3,4 active trachoma
occurs in adults, and high rates of scarring and trichiasis are
observed. The greatest load of chlamydial infection also ap-
pears to be in children aged 10 years, reaffirming that young
children are the primary reservoir of infection for the commu-
nity.5 Adults also carry infection in these communities, and
although the load may be lower, transmission may still be
possible, and the presence of chlamydial antigen may continue
to stimulate the scarring process.6–8
The purpose of this study was twofold. First, we charac-
terized the load of Chlamydia trachomatis in a hyperen-
demic community by using quantitative PCR and determined
the characteristics of those with high chlamydial loads. Sec-
ond, we evaluated the effect of treatment on chlamydial load
within the community, to determine whether single-dose treat-
ment with azithromycin eliminates infection. Such data are
critical for determining the most effective treatment strategies
in a trachoma-endemic community to decrease transmission.
METHODS
This study was performed in the village of Maindi in Kongwa, Tanzania.
The longitudinal study has been described in detail elsewhere and is
summarized herein for the Kongwa component.5,6 Research and eth-
ical clearances for all procedures were obtained from the Tanzanian
government through the National Institute for Medical Research Insti-
tute (NIMR) and through the Johns Hopkins University Institutional
Review Board. The study conformed to the tenants of the Declaration
of Helsinki.
A baseline census of every household was taken, and a number was
applied to the doorway to enable mapping of the geographical location
of every house in the village. The census included details on the age,
gender, and relationship to head of household of every household
member. Household characteristics also were collected, including
whether the household was part of a larger compound of contiguous
households called a “kaya.”
After the census, a baseline survey was conducted targeting every-
one in the village. Trachoma was assessed according to the WHO
simplified grading scheme by an experienced trachoma grader who
used 2.5 loupes.9 An ocular specimen was collected for detection of
ocular C. trachomatis infection and quantification of infection by
real-time PCR (Amplicor; Roche Molecular Systems, Branchburg, NJ),
as described in detail elsewhere.5 A sterile Dacron swab was held
horizontally and passed across the length of the tarsal conjunctiva four
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times, with the swab rotated a quarter turn with each pass. To ensure
consistency in the swab procedures, a single individual was responsi-
ble for taking all swabs. Precautions were taken to prevent cross-
contamination. Specifically, we ensured that the Dacron tip did not
touch anything besides the conjunctiva and the inside of the transport
tube, as scissors were not used to cut the swab shaft. The laboratory
person did not touch any subject or staff member during the taking of
specimens. He also cleaned his hands thoroughly with alcohol be-
tween taking specimens. Longitudinal surveys using the same methods
were performed on everyone in the village at 2 months.
Each swab was placed dry in a vial, kept cold on frozen freezer
blocks in the field for the day, and stored at 20°C until shipped on
freezer blocks to the London School of Hygiene and Tropical Medicine
for processing. A C. trachomatis qualitative PCR assay was used to
identify samples positive for the organism (Amplicor; Roche Molecular
Systems). Details on processing the samples have been described in a
previous paper,5 but in essence, PCR was performed on eluted samples
according to the manufacturer’s instructions. Testing for PCR inhibi-
tion was performed. If there was evidence of inhibition, samples were
retested after diluting an aliquot 1:5 with a 50:50 mixture of lysis buffer
(Amplicor CT/NG; Roche Molecular Systems) and specimen diluent.
Positive and negative results were then assigned as outlined by the
manufacturer. Samples that initially returned equivocal results were
designated positive or negative according to the manufacturer’s pro-
tocol. All positive samples were then processed for quantity of omp1
(the genomic equivalent of C. trachomatis), with a quantitative PCR
assay developed and described previously.5
Real-time quantitative PCR was performed on a thermocycler
(LightCycler; Roche Molecular Systems). The target for quantitative
PCR amplification was a 123-bp fragment within constant domain 3 of
the omp1 gene. Each elementary body contains a single copy of this
gene. For each sample, quantification was performed twice on two
replicate aliquots.5 Everyone older than 6 months in the village was
offered a single dose of oral azithromycin, 20 mg/kg up to a 1-g dose.
Children aged2 years were weighed to determine the proper dosage.
Children aged 6 months were not treated. Women who stated they
were pregnant were offered topical tetracycline if they had no signs of
trachoma. Otherwise, they were treated with azithromycin.
Quantification is reported as the number of organisms per swab,
as described earlier.5 Some samples were Amplicor positive, yet
LightCycler negative, on one or both runs. These samples were cate-
gorized as positive for reasons described elsewhere, and maximum-
likelihood estimations were used to impute the number of organisms
likely to be contained in the swab.5 In this article, we refer to loads less
than or equal to the median load as “low loads” and loads greater than
the median as “high loads.” Logistic regression analyses were used to
determine the independent contribution of factors to the risk of having
an infectious load greater than median value before treatment. General
estimating equation (GEE) models with independent correlation struc-
tures were used to adjust the confidence intervals for clustering of risk
factors at the kaya (household compound) level.
RESULTS
The census tabulated 1020 persons in the village at baseline, of
whom 876 (86%) participated in the baseline survey. Individ-
uals who did not participate in the survey were more likely to
be male (P  0.007) and aged 11 to 30 years (P  0.01) than
participants. Data on infection obtained by the Amplicor test
(Roche Molecular Systems) were available for all but three of
the participants. Quantitative data were missing on 88 Ampli-
cor-positive specimens at baseline, due to loss of sample at the
laboratory. Participants with missing quantitative data were
more likely to be aged 16 to 20, 22% versus 11% of those not
missing data (P 0.015). Participants missing quantitative data
were less likely to be 10 years, but there were no differences
by gender or household size. Less than 1% of the entire group
lived in households with three or fewer persons, and 90% lived
in households with six or more persons.
At baseline, 496 (57%) participants were Amplicor positive.
Among this group, we examined the distribution of C. tracho-
matis by age and gender (Table 1). The data show the greatest
concentration of chlamydial load was in the youngest age
groups. Children 7 years carried 90% of the total community
load of C. trachomatis. Below age 30 years, more of the total
community load by age group was in females than in males.
Above age 30, infection rates were lower in both sexes, and
four males with very high loads (150 omp1 units) accounted
for a greater total load in males, as 55% of persons 30 years
of age had no infection. Individuals with loads above the
median value (19.1 omp1 copies) were seen in all age groups
in this community (Fig. 1). Overall, 22% (173/785) of the
population had high loads at baseline. Children aged10 years
were more likely to have high loads than were older persons
(P  0.001).
The proportion of individuals with high loads at baseline
increased with severity of clinical sign (Table 2). Only 8% of
individuals with no clinical sign of active trachoma (using the
WHO simplified system) had high loads, whereas 40% of those
with trachomatous follicles (TF) alone and 51% of those with
severe inflammatory trachoma (TI) had high loads.
TABLE 1. Baseline Distribution of Chlamydial Load in Those Who Have Infection, and the Percentage with Infection, by Age and Gender, in a
Population in Maindi, Tanzania*
Age
Males Females
n
Total Load
(Copies)†
% With Any
Infection
% With Active
Disease§ n
Total Load
(Copies)†
% With Any
Infection
% With Active
Disease§
5 81 3,062,021 74 81 100 6,936,028 69 78
6–10 67 572,726 51 59 77 1,680,947 62 67
11–20 86 135,896 37 20 95 223,926 56 36
21–30 44 206 39 2 73 13,481 47 13
31–40 27 15,945 37 3 42 543 36 4
41–50 19 898 37 0 23 140 35 4
51 21 113,882‡ 52 8 30 9027 37 6
Total 345 3,901,574 50 36 440 8,864,092 54 40
* Excluding 88 participants who were positive for infection but are missing quantitative data and three individuals who did not provide a
specimen.
† Total omp1 copies per swab.
‡ One individual accounted for 113,778 copies of this load.
§ Active disease: TF and/or TI.
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Of particular interest, 23% (39/173) of those with a high
load had no active trachoma. Most of these, 72%, were indi-
viduals aged 11 years. Moreover, one fourth of those with
high loads and no active trachoma lived in households where
no one else had trachoma. These analyses suggest no obvious
markers of clinical disease or age for finding one quarter of
individuals who have high loads of infection and who, there-
fore, could be sources of transmission.
Young age, female gender, and a high proportion of indi-
viduals with high chlamydial loads at baseline living in the
same kaya were independent predictors of a high chlamydial
load at baseline (Table 3). The higher the proportion of the
kaya members that were infected, the greater the likelihood
that the participant had a high load at baseline. In fact, indi-
viduals living in a kaya where 50% of the other members
were infected were 7.2 times more likely to have high loads at
baseline than individuals living in a kaya where no other per-
son had a high load (95% confidence interval [CI]: 1.9–27.3).
Tin roofs, presence of flies and presence of a latrine were not
predictive of high load at baseline (data not shown).
Treatment coverage of this population was high, with 86%
of persons receiving treatment. Among children aged 10
years, coverage was 90%. Treatment resulted in a dramatic
decline in the chlamydial load (Table 4). However, clearance of
FIGURE 1. Distribution of chlamydial load in the total population by age and gender.
TABLE 2. Number and Percentage of Individuals with No, Low, or
High Chlamydial Load at Baseline, According to Clinical
Signs of Disease
Clinical
Sign
Chlamydial Load
TotalNone <Median Load* >Median Load
No TF or TI 294 (62%) 143 (30%) 39 (8%) 476
TF only 64 (29%) 66 (30%) 87 (40%) 217
TI  TF 19 (21%) 26 (28%) 47 (51%) 92
Total 377 (48%) 235 (30%) 173 (22%) 785
* 19.1 omp1 copies, includes samples that were Amplicor pos-
itive but LightCycler negative (Roche Molecular Systems). Chlamydial
load was determined by the number of omp1 copies per swab. 2 
157.4, P  0.0001.
TABLE 3. Predictors of Having a High Chlamydial Load at Baseline
n OR 95% CI
Age (y)
0–5 75/181 9.3 4.8–18.0
6–10 41/144 5.6 3.0–10.5
11–20 34/181 2.8 1.5–5.4
21–30 10/117 1.1 0.6–2.1
31 13/162 Ref. —
Gender
Female 106/440 1.5 1.0–2.1
Male 67/345 Ref. —
Proportion of remainder of kaya
with high loads (%)
0 25/208 Ref. —
25 67/349 1.8 0.8–4.1
25–50 64/187 4.3 1.8–10.0
50 17/41 7.2 1.9–27.3
Using multivariate logistic regression with generalized estimating
equations. OR, odds ratio; CI, confidence interval.
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infection with no evidence of infection at 2 months declined
with increasing load at baseline. Whereas 91% of individuals
with a low load at baseline had no infection at 2 months, only
74% of participants with 20 omp1 copies had no infection at
2 months after treatment (P  0.05). Of the 33 participants
with high load at baseline who also were infected at 2 months,
half also had a high load at 2 months. Only one person in the
treated population with no or low load at baseline had a high
load at 2 months.
The 15 persons who, despite being treated, had high loads
again at 2 months are of particular interest, as they represent
those individuals who are liable to reinfect others after mass
treatment. Among the 162 persons with high loads who were
treated, most were persons aged 20 (88%) years, and most
(74%) had no infection at 2 months (Table 5). However, all but
one of those who had high loads at both time points were aged
10 years, compared with 67% of those who were infected at
baseline but had no infection at 2 months. In fact, most (9/15)
were aged 2 years.
DISCUSSION
In this trachoma-hyperendemic community, infection and high
chlamydial loads were present in all age and gender groups.
High chlamydial loads were most commonly recorded in
younger children and in individuals with clinical trachoma.
Those with high loads, defined as greater than median chla-
mydial load, or19.1 omp1 copies, are a critical group, as they
are likely to be responsible for transmission within the house-
hold and community. They are also a significant fraction of the
population, 22%. Our data suggest that although a significant
proportion of those with high loads had clinical signs, 23% did
not. These individuals tended to be older persons, and some
did not reside in households with persons who had clinical
signs. Burton et al.6 found that in hypoendemic villages in The
Gambia, most persons with infection did not have clinical
signs, although similar to our findings, the prevalence of infec-
tion increased with increasing severity of clinical trachoma. In
the Gambian population, the prevalence of infection did not
vary by age, and only 69% of the chlamydial load was in those
aged 10 years. In both our population and in a mesoendemic
population in northern Tanzania, 90% of the burden was
among children aged 7 years.5
It is of interest to determine how many persons with high
loads in our population would not be treated by using cur-
rently discussed treatment strategies for trachoma control. The-
oretically, with mass treatment, all would be targeted and
treated, and in fact, in our population, 96% of those with high
loads were treated, with overall coverage of the population at
86%. Some programs target only children aged 10 years.11 If
only children aged 10 years are treated, 69% of those with
high load are covered. If treatment were extended to house-
holds with children aged 10 years, 90% of the entire popu-
lation would be targeted, because most people live in house-
holds with children. Given this, it is more practical to
undertake mass treatment.
Treating only persons aged 20 years would cover 90% of
high loads, and 71% of those with any infection, while target-
ing 65% of the village population. This approach may seem
appealing, as it covers most persons with high loads and may
be expected to impact on transmission. However, treatment
would not be provided to older adults, who harbor 10% of high
loads, or to individuals who have low levels of infection and
may still be at risk of ongoing scarring.
Treatment targeted toward individuals with clinical tra-
choma would miss 23% of those with high loads. In The
Gambia, targeting active cases would capture only 25% of
individuals with infection and 25% of those with high loads.6
Others have shown that treatment targeted toward clinically
active cases is not cost-effective compared with mass treat-
ment.10 Although treating persons with active cases and their
households misses only 6% of high loads, it still targets 82% of
the population and requires screening of every household.
Thus, we conclude that mass treatment of the population is
still the best approach for hyperendemic communities, pro-
vided high coverage is achieved. As we monitored persons for
only 2 months for these analyses, we cannot project likely
follow-up treatment strategies or frequency.
A novel and significant finding is the large proportion of
children aged2 years with high ocular chlamydial loads, who
remained infected 2 months after treatment. Solomon et al.5
also have found very high loads in children 1 year old in two
other trachoma-endemic areas. In the present study, antibiotic
treatment was provided by a weight-based approach and di-
rectly observed by research staff, so that undertreatment was
unlikely to occur.11 Of children aged 2 years, 47% had high
loads at baseline. Of the two children in this age group who
were not treated, both had high loads at 2 months. Of the
children this age who had high loads and were treated, 31%
(n  9) had high loads at 2 months, representing 50% of
those who had high loads at both time points, despite treat-
ment. It is unlikely that many of these children were reinfected
so quickly, as they either resided in households where every-
one was treated or in households where individuals not treated
did not have infection. However, we did not treat children
aged6 months for trachoma, nor were they examined. These
infants could serve as a source of reinfection, as three of the
nine children with high loads at both time points lived in
households with infants. They may represent errors in mea-
surement of weight or persons for whom a dose greater than
20 mg/kg is needed for cure. It would be interesting to deter-
mine the antimicrobial susceptibility of C. trachomatis strains
isolated from these children.
There are limitations to our study. The results are based on
a large hyperendemic community in Tanzania, but village prev-
alence can vary.12 It is reassuring that prevalence of infection
and correlation with clinical disease are similar to that previ-
ously found in other villages in Kongwa.4,13 The effect of mass
TABLE 5. Age Distribution of Participants with High Chlamydial Load
at Baseline and No Infection after Treatment, compared with the
Age Distribution of Participants with High Loads at both Time
Points, among Persons Treated
Age Group (y) of
Individuals with High
Baseline Load
No Infection
after Treatment
High Load
of Infection
after Treatment
5 38 (41%) 13 (87%)
6–10 24 (26%) 1 (7%)
11 31 (33%) 1 (7%)
Fisher exact test, P  0.004.
TABLE 4. Effect of Mass Treatment on Chlamydial Load at 2 Months
after Treatment, According to Baseline Load, among Persons Treated
Baseline Load
(omp1 Copies) n 0 Copies
1–<20
Copies
20
Copies
0 247 236 (95.6) 10 (4.0) 1 (0.4)
1–20 169 153 (90.5) 16 (9.5) 0 (0)
20 126 93 (73.8) 18 (14.3) 15 (11.9)
Total 542 482 (88.9) 44 (8.1) 16 (3.0)
Data are expressed as the number (%) with no, low, and high load
at 2 months. Fisher exact test, P  0.0001.
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treatment with azithromycin also had effects on infection sim-
ilar to that observed in previous studies.14
There is always the theoretical concern for contamination
of specimens during collection in the field. We instituted strict
procedures for specimen collection, including having the field
laboratory person never touch participants or other team mem-
bers during collection and the swabs never touch anything
other than the eyelid or the interior of the sterile vial. We also
are reassured that contamination did not occur, because eval-
uation of the order of specimens collected and positivity rates
showed that among persons from whom a specimen was
collected immediately after a person with high load that was
not a family member, only 31% had a high load. This percent-
age is comparable to persons negative for ocular chlamydia.
Thirty-six percent of individuals who were examined after a
person (not a family member) without chlamydia had a high
load. Although some contamination may always be possible, it
is unlikely to explain our findings on heavy loads. Because of
the high prevalence of low loads of infection, we cannot rule
out contamination of specimens in the field or laboratory as a
possible explanation of persons with low loads.
Another limitation was the lack of treatment and examina-
tion of infants aged 6 months. The Tanzania National Treat-
ment Control Program did not authorize treatment of infants
age 6 months, and such children are difficult to access in
Kongwa for several cultural reasons. They may be a source of
re-emergent infection, although there were few of them at the
time of treatment.
In summary, data on the load of C. trachomatis infection in
this hyperendemic community confirm that a significant por-
tion of the infectious load resides in young children. However,
there are adults, including those with no clinical signs of
trachoma, who also carry high loads and could be another
source of transmission in this community. Such data support
the mass-treatment approach to trachoma control in hyperen-
demic villages. Although treatment was effective in decreasing
the community pool of infection, it appeared to be least effec-
tive in very young children with high loads, half of whom still
had high loads 2 months later. The causes of this persistence or
re-emergence in very young children should be further inves-
tigated.
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